In this issue:
KEYNOTE-564: Adjuvant pembrolizumab prolongs DFS in RCC
CheckMate 914: No benefit to adjuvant doublet immunotherapy in RCC
TKI holidays don’t substantially impair efficacy in RCC
Front-line and salvage immunotherapy for non-clear cell RCC
Aboriginal patients at greater risk of penile cancer-specific mortality
Outcomes for men in remission from testicular GCTs
Lenvatinib/pembrolizumab efficacious for Asian patients with RCC
Real-world safety of radiotherapy plus cabozantinib for metastatic RCC
Bilateral ILND may not be necessary for cN1 penile cancer
Post-transplant etoposide promising for platinum-refractory GCTs
Please login below to download this issue (PDF)